BACKGROUND: During the past decade, in the United States, an increasing number of hepatitis B outbreaks have been reported in assisted living facilities (ALFs) as a result of breaches in infection control practices. We evaluated the seroprotection rates conferred by hepatitis B vaccine among older adults during a response to an outbreak that occurred in multiple ALFs and assessed the influence of demographic and clinical factors on vaccine response. METHODS: Residents were screened for hepatitis B and C infection prior to vaccination and susceptible residents were vaccinated against hepatitis B with one dose of 20 μg Engerix-B™ (GSK) given at 0, 1, and 4 months. Blood samples were collected 80-90 days after the third vaccine dose to test for anti-HBs levels. RESULTS: Of the 48 residents who had post-vaccination blood specimens collected after the third vaccine dose, 16 (33.3%) achieved anti-HBs concentration ≥10 mIU/mL. Age was a significant determinant of seroprotection with rates decreasing from 88% among persons aged ≤60 years to 12% among persons aged ≥90 years (p=0.001). Geometric mean concentrations were higher among non-diabetic than diabetic residents, however, the difference was not statistically significant (5.1 vs. 3.8 mIU/mL, p=0.7). CONCLUSIONS: These findings highlight that hepatitis B vaccination is of limited effectiveness when administered to older adults. Improvements in infection control and vaccination at earlier ages might be necessary to prevent spread of infection in ALFs. Published by Elsevier Ltd.
BACKGROUND: During the past decade, in the United States, an increasing number of hepatitis B outbreaks have been reported in assisted living facilities (ALFs) as a result of breaches in infection control practices. We evaluated the seroprotection rates conferred by hepatitis B vaccine among older adults during a response to an outbreak that occurred in multiple ALFs and assessed the influence of demographic and clinical factors on vaccine response. METHODS: Residents were screened for hepatitis B and C infection prior to vaccination and susceptible residents were vaccinated against hepatitis B with one dose of 20 μg Engerix-B™ (GSK) given at 0, 1, and 4 months. Blood samples were collected 80-90 days after the third vaccine dose to test for anti-HBs levels. RESULTS: Of the 48 residents who had post-vaccination blood specimens collected after the third vaccine dose, 16 (33.3%) achieved anti-HBs concentration ≥10 mIU/mL. Age was a significant determinant of seroprotection with rates decreasing from 88% among persons aged ≤60 years to 12% among persons aged ≥90 years (p=0.001). Geometric mean concentrations were higher among non-diabetic than diabetic residents, however, the difference was not statistically significant (5.1 vs. 3.8 mIU/mL, p=0.7). CONCLUSIONS: These findings highlight that hepatitis B vaccination is of limited effectiveness when administered to older adults. Improvements in infection control and vaccination at earlier ages might be necessary to prevent spread of infection in ALFs. Published by Elsevier Ltd.
Authors: P Rendi-Wagner; M Kundi; H Stemberger; G Wiedermann; H Holzmann; M Hofer; K Wiesinger; H Kollaritsch Journal: Vaccine Date: 2001-02-28 Impact factor: 3.641
Authors: Ami S Patel; Mary Beth White-Comstock; C Diane Woolard; Joseph F Perz Journal: Infect Control Hosp Epidemiol Date: 2009-03 Impact factor: 3.254
Authors: Celine A Hayden; Stephen J Streatfield; Barry J Lamphear; Gina M Fake; Todd K Keener; John H Walker; John D Clements; Debra D Turner; Ian R Tizard; John A Howard Journal: Vaccine Date: 2012-03-08 Impact factor: 3.641
Authors: Celine A Hayden; Erin M Egelkrout; Alessa M Moscoso; Cristina Enrique; Todd K Keener; Rafael Jimenez-Flores; Jeffrey C Wong; John A Howard Journal: Plant Biotechnol J Date: 2012-07-21 Impact factor: 9.803
Authors: Celine A Hayden; Emily M Smith; Debra D Turner; Todd K Keener; Jeffrey C Wong; John H Walker; Ian R Tizard; Rafael Jimenez-Flores; John A Howard Journal: Vaccine Date: 2014-01-28 Impact factor: 3.641
Authors: Thomas John Bender; Umid Sharapov; Okey Utah; Jian Xing; Dale Hu; Jolanta Rybczynska; Jan Drobeniuc; Saleem Kamili; Philip R Spradling; Anne C Moorman Journal: Vaccine Date: 2013-12-23 Impact factor: 3.641
Authors: Miguel Ángel Palacios-Pedrero; Albert D M E Osterhaus; Tanja Becker; Husni Elbahesh; Guus F Rimmelzwaan; Giulietta Saletti Journal: Front Immunol Date: 2021-05-12 Impact factor: 7.561
Authors: Olivier Van Der Meeren; James T Peterson; Marc Dionne; Richard Beasley; Peter R Ebeling; Murdo Ferguson; Michael D Nissen; Paul Rheault; Richard W Simpson; Marc De Ridder; Priya D Crasta; Jacqueline M Miller; Andrew F Trofa Journal: Hum Vaccin Immunother Date: 2016-04-28 Impact factor: 3.452